New Drug Update 2010-2011 Faculty Disclaimer - CME Conferences

2 nd Annual Essentials in Primary Care
Fall Conference
Friday, November 11, 2011
Linagliptin – Tradjenta
• There have been no clinical studies
establishing conclusive evidence of
macrovascular or microvascular risk reduction
with linagliptin
• Linagliptin has not been studied in
combination with insulin
• Linagliptin is an alternative to sitagliptin and
saxagliptin for the treatment of patients with
type 2 diabetes and it does not need a dosage
reduction in patients with renal dysfunction.
Pancreatitis, Pancreatic, and Thyroid
Cancer With Glucagon-Like
Peptide-1–Based Therapies
GASTROENTEROLOGY 2011;141:150–156
• US Food and Drug Administration’s database of reported
adverse events for those associated with the dipeptidyl
peptidase4 inhibitor sitagliptin and the glucagon-like peptide-
1 mimetic exenatide, from 2004-2009; data on adverse events
associated with 4 other medications were compared as
controls.(rosiglitazone, nateglinide, repaglinide and glipizide)
• The primary outcomes measures were rates of reported
pancreatitis, pancreatic and thyroid cancer, and all cancers
associated with sitagliptin or exenatide, compared with other
therapies.
Wayne Weart
New Drug Update Part I